MyoVista wavECG (DG-200-B15-003)
HeartSciences, Inc. · Decision date Oct 5, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-05 for MyoVista wavECG (DG-200-B15-003), submitted by HeartSciences, Inc. of Southlake, Texas, under 510(k) number K260005. The device is listed under the classification name Electrocardiograph, regulation 870.2340, product code DPS, with a Cardiovascular medical specialty and review panel. The application was received on 01/02/2026 and is a Traditional 510(k); the page states it was not reviewed by a third party, is not a combination product, and has no authorized Predetermined Change Control Plan.
SESE denotes clearance to market, not premarket approval. The public record does not describe the specific components, design changes, or performance data supporting the equivalence determination, and no summary statement content is included here. Whether the submission relied on a predicate device, and which one, is not shown in the available fields.
The page was last updated 11/09/2026. Details of the cleared indications, comparison device, and any testing remain in the underlying FDA documents rather than this database entry.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 5, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260005
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- HeartSciences, Inc.
- Product code
- DPS
- Decision code
- SESE
- Decision date
- Oct 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Electrocardiograph.
- Applicant
- HeartSciences, Inc.
- Product code
- DPS
- FDA device class
- 2
FDA decision timeline
K260005 received
Application receipt date recorded by FDA.
K260005 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DPS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Kinetic Software LibraryK260640 | Monebo Technologies, Inc. | 510(k) clearance | Oct 23, 2026 | FDA |
| QT Medical, Inc. | 510(k) clearance | Sep 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
HeartSciences, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Southlake, TX
Sources and methodology
- Original FDA record: K260005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
